With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...

The late-stage readout suggests that HRS9531 can hold its own against Eli Lilly’s blockbuster GLP-1/GIP agonist Zepbound, ...

Days after JCR Pharmaceuticals signed a deal with AstraZeneca’s rare disease unit, the Japanese biopharma has secured a ...

The Department of Health and Human Services (HHS) is laying off certain employees that were notified months ago of the ...

Zimmer Biomet inked a $177 million deal to purchase Monogram Technologies, developer of a hands-free robotic surgery system ...

After 45 years at Henry Schein, including more than three decades as its CEO, Stanley Bergman has announced plans to retire ...

The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said it will pay up to $951 million to acquire LaNova Medicines, which has ...

Sellas Life Sciences’ investigational CDK9 inhibitor has scored in a midstage acute myeloid leukemia (AML) study, demonstrating an overall response rate (ORR) more than double the 20% goal.